In the Specification

Please amend the paragraph beginning at page 3, line 3, as follows:

Namely, the invention relates to a solid preparation with a coating around the core containing a gene-related drug for oral administration with ~~relesablity~~ releasability in lower digestive tracts in small intestines is applied.

Please amend the paragraph beginning at page 4, line 21, as follows:

The above solid preparations for oral administration wherein the saccharide are monosaccharides and ~~disacchaarides~~ disaccharides such as lactose, fructose, sucrose, glucose, xylitol, maltose, ~~mannnitol~~ mannitol and sorbitol, or polysaccharides and derivatives thereof such as cellulose, crystalline cellulose, hydroxypropyl cellulose, hydroxyethylmethyl cellulose, ethyl cellulose, starch, dextrin, dextran, pectin and pullulan.

Please amend the paragraph beginning at page 5, line 25, as follows:

The above solid preparations for oral administration wherein the gene-related drugs comprise a nucleic acid, oligonucleotide, antisense, triple helix forming ~~olignucleotide~~ oligonucleotide (TFO), ribozyme, decoy, plasmid, cosmid, P1 phage, YAC (yeast artificial chromosome), chromosome, aptamer and phage.

Please amend the paragraph beginning at page 6, line 9, as follows:

In the invention, illustrative of available gene-related drugs are DNA, RNA and modified compounds thereof, and compounds thereof conjugated or bound to a carrier, nucleic acid, oligonucleotide, antisense, triple helix forming ~~olignucleotide~~ oligonucleotide (TFO), ribozyme,

decoy and plasmid. Illustrative of the carriers used are cationic polymer, cationic lipid, virus vector and phage.

Please amend the paragraph beginning at page 6, line 16, as follows:

Specifically, in the case of aiming at the colitis therapy as a topical therapeutic use are illustrated suppressive type gene pharmaceuticals such as TNF-α (Tumor necrosis factor α), ICAM-1 (Intercellular adhesion molecule-1), COX-2 (Cyclooxygenase-2), IL-1 (Interleukin-1), IL-6 (Interleukin-6) and IL-8 (Interleukin-8), or expression type gene pharmaceuticals such as IL-2 (Interleukin-2) and IL-10 (Interleukin-10). In the case of aiming at the colon cancer are illustrated suppressive type gene pharmaceuticals such as ICAM-1, COX-2 and TGF-β (Transforming growth factor β), or expression type gene pharmaceuticals such as INF-γ (Interferon-γ), TNF-α, APC (Adenomatous Polyposis Coli), p53, MCC (Mutated in ~~Cololateral~~ Colorectal Carcinoma) and DCC (deleted ~~on~~ in colorectal carcinomas). Further, in the case of aiming at the systemic diseases are illustrated suppressive type gene pharmaceuticals such as TNF-α, ICAM-1, COX-2, IL-1, IL-6, HIV (human immunodeficiency virus), bile acid transporter and each transporter of the small intestine, or expression type gene pharmaceuticals such as INF-γ, TNF-α, G-CSF (Granulocyte colony-stimulating ~~facor~~ factor), GM-CSF (Granulocyte macrophage colony-stimulating ~~facor~~ factor), glucose transporter, LHRH (~~Luteonizing~~ Luteinizing hormone-releasing hormone) and calcitonin.

Please amend the paragraph beginning at page 9, line 9, as follows:

Here, illustrative of the saccharide are monosaccharides and disaccharides such as lactose, fructose, sucrose, glucose, xylitol, maltose, ~~mannitol~~ mannitol and sorbitol, or polysaccharides and derivatives thereof such as cellulose, crystalline cellulose, hydroxypropyl cellulose, hydroxyethylmethyl cellulose, ethyl cellulose, starch, dextrin, dextran, pectin and pullulan. Preferably lactose is used.

Please amend the paragraph beginning at page 9, line 25, as follows:

The mixed ratio of the excipient contained in the core containing the gene-related drug is 2-25 wt.%., preferably 5-15 wt.%., likewise the mixed ratio of the sugar is 20-60 wt.%., preferably 30-50 wt.%. The mixed ratio of the disintegrator against the mixed amount of the gene-related drug is in the range preferable for having a suitable ~~disintegrastion~~ disintegration in order to be delivered to the target site in the digestive tracts and for the compressibility, specifically in the ratio of 1:0.05-1:10, preferably 1:0.1-1:5. The mixed ratio of ~~cross-povidone~~ crospovidone as the disintegrator is in the range of 2.5-20 wt.%., preferably 5-15 wt.%.

Please amend the paragraph beginning at page 13, line 9, as follows:

The tablets containing the TNFα antisense produced by the above procedures were produced according to the following formulation in Table 2-1 and Table 2-2. First, the TNFα antisense and light anhydrous silicic acid, or the TNFα antisense, crystalline cellulose and light anhydrous silicic acid were mixed and ground using a grinding machine, subsequently added with lactose and ~~cross-povidone~~ crospovidone, mixed, finally added with magnesium stearate, and mixed. The mixture was compressed using a tablet machine to produce tablets having the diameter of 7 mm and the weight of 200 mg.